Clinical Trials · NCT02976038
Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 28
- Start date
- Dec 2016
- Locations
- 4 sites, United States
- Primary endpoint
- Distance Walked on Six Minute Walk Test